Retatrutide is a synthetic peptide developed as a simultaneous agonist of the GLP-1, GIP and glucagon receptors. It is one of the most investigated compounds of the moment in metabolic pharmacology.
The physiological logic of triple activation
Each component contributes a complementary effect in animal models:
- GLP-1-R: glucose-dependent insulin secretion, central appetite suppression (via the arcuate nucleus), slowing of gastric emptying.
- GIP-R: potentiation of the incretin response, modulation of lipid metabolism in adipocytes.
- Glucagon-R: increase in basal energy expenditure, hepatic lipolysis, thermogenesis. This component is what sets retatrutide apart from the rest of the class.
Pharmacokinetics
Retatrutide uses a fatty acid acylation strategy for albumin conjugation, similar to tirzepatide and semaglutide. Its average half-life reported in phase 1 studies is around 150 hours, which allows weekly dosing in clinical protocols.
Phase 2 clinical research results
In the trial by Jastreboff et al. (2023) published in NEJM, retatrutide 12 mg weekly in cohorts with obesity showed an average body weight reduction of 24% at 48 weeks — the highest result reported to date for an incretin agonist. Important: this figure comes from a controlled clinical trial and should not be interpreted as a recommendation for use.
Marcadores secundarios observados
- Significant reduction of visceral fat mass measured by MRI.
- Decreased liver triglyceride content (relevant for NAFLD research).
- Improvement in lipid profile (LDL, triglycerides).
- A moderate increase in resting heart rate — an effect shared with other incretin agonists and partly attributable to the glucagon component.
Puntos abiertos
- Long-term data (more than 2 years) not yet published.
- Behavior in cohorts with pre-existing liver dysfunction.
- Full characterization of the adverse effect profile at high doses (12+ mg).
Conclusion
Retatrutide represents the maturing of a hypothesis: that coordinated activation of the three main incretin receptors can translate into a metabolic effect greater than the sum of its parts. Preliminary data support this hypothesis, but the field awaits long-term safety data.
🔬 Updated on February 3, 2026 · Reviewed by the NeoPeptidos team · Content for research purposes (RUO).